Targeting tumours with genetically enhanced T lymphocytes

被引：416

作者：

Sadelain, M

Rivière, I

Brentjens, R

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA

来源：

NATURE REVIEWS CANCER | 2003年 / 3卷 / 01期

关键词：

D O I：

10.1038/nrc971

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The genetic modification of T lymphocytes is an important approach to investigating normal T-cell biology and to increasing antitumour immunity. A number of genetic strategies aim to increase the recognition of tumour antigens, enhance antitumour activities and prevent T-cell malfunction. T cells can also be engineered to increase safety, as well as to express markers that can be tracked by non-invasive imaging technologies. Genetically modified T cells are therefore proving to be of great value for basic immunology and experimental immunotherapy.

引用

收藏

页码：35 / 45

页数：11

相关论文

共 134 条

[1] Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 [J].

Agrawal, B ;

Krantz, MJ ;

Reddish, MA ;

Longenecker, BM .

NATURE MEDICINE, 1998, 4 (01) :43-49

[2]

Altenschmidt U, 1996, CLIN CANCER RES, V2, P1001

[3]

Altenschmidt U, 1997, J IMMUNOL, V159, P5509

[4] Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors [J].

AlvarezVallina, L ;

Hawkins, RE .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (10) :2304-2309

[5] Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: The dynamics of T-cell proliferation and death [J].

Beecham, EJ ;

Ma, QZ ;

Ripley, R ;

Junghans, RP .

JOURNAL OF IMMUNOTHERAPY, 2000, 23 (06) :631-642

[6] Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor [J].

Beecham, EJ ;

Ortiz-Pujols, S ;

Junghans, RP .

JOURNAL OF IMMUNOTHERAPY, 2000, 23 (03) :332-343

[7] In vivo imaging of gene delivery and expression [J].

Bogdanov, Alexei, Jr. ;

Weissleder, Ralph .

TRENDS IN BIOTECHNOLOGY, 2002, 20 (08) :S11-S18

[8] CD28 COSTIMULATION CAN PROMOTE T-CELL SURVIVAL BY ENHANCING THE EXPRESSION OF BCL-X(L) [J].

BOISE, LH ;

MINN, AJ ;

NOEL, PJ ;

JUNE, CH ;

ACCAVITTI, MA ;

LINDSTEN, T ;

THOMPSON, CB .

IMMUNITY, 1995, 3 (01) :87-98

[9] Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity [J].

Bollard, CM ;

Rössig, C ;

Calonge, MJ ;

Huls, MH ;

Wagner, HJ ;

Massague, J ;

Brenner, MK ;

Heslop, HE ;

Rooney, CM .

BLOOD, 2002, 99 (09) :3179-3187

[10] Tumor antigens [J].

Boon, T ;

Old, LJ .

CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (05) :681-683

← 1 2 3 4 5 6 7 8 9 10 →